Clinical Trials Logo

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) and best supportive care (BSC) compared to placebo and BSC in treatment of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01100502
Study type Interventional
Source Seagen Inc.
Contact
Status Completed
Phase Phase 3
Start date April 30, 2010
Completion date April 27, 2020

See also
  Status Clinical Trial Phase
Completed NCT00430846 - Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies Phase 1
Terminated NCT00649584 - A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies Phase 1
Completed NCT00947856 - A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study Phase 2
Completed NCT01026233 - Cardiac Safety Study of Brentuximab Vedotin (SGN-35) Phase 1
Completed NCT01060904 - A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma Phase 1
Completed NCT00848926 - A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma Phase 2
Completed NCT01026415 - Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) Phase 1
No longer available NCT01196208 - A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001